## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

## Listing of Claims:

Claim 1 (previously presented): A method of inducing, in a human, serum antibodies which protect against infection with S. *typhi*, comprising administering to said human, a composition comprising a molecular conjugate of the S. *typhi* Vi polysaccharide comprising an N-acetyl group and covalently bound through a carboxylic acid dihydrazide linker to *Pseudomonas aeruginosa* recombinant exoprotein A in a pharmaceutically acceptable carrier.

Claim 2 (canceled)


Claim 2 (previously presented): The method of claim 1 wherein said conjugate molecule is administered at a dose of about 3 micrograms to about 50 micrograms of S. *typhi* Vi polysaccharide.

Claim 4 (original): The method of claim 3 wherein said conjugate molecule is administered at a dose of about 25 micrograms of Vi polysaccharide.

Claim 8 (previously amended): The method of claim 1 wherein the antibodies protect the human against infection by S. typhi.

Claims 6-11 (canceled)

Claim 12 (currently amended): A method for vaccinating a human against S. typhi infection, comprising administering to the human an immunizing amount of a composition comprising a molecular conjugate of S. typhi Vi polysaccharide comprising an N-acetyl group and covalently bound through a carboxylic dihydrazide linker of Pseudomonas aeruginosa recombinant exoprotein A in a pharmaceutically acceptable carrier[[,]].



Claim 13 (canceled)

Claim 14 (previously presented): A vaccine composition comprising an immunologically effective amount of a molecular conjugate of S. *typhi* Vi polysaccharide comprising an N-acetyl group and covalently bound through a carboxylic acid dihydrazide linker to *Pseudomonas* aeruginosa recombinant exoprotein A, in a pharmaceutically acceptable carrier.

Claim 15 (canceled)

Claim 16 (original): The method of claim 5 wherein the human is a 2 to 3 year old.

Claim 19 (original): The method of claim 5 wherein the human is a 4 to 5 year old.

Claim 18 (original): The method of claim 8 wherein the human is a 5 to 17 year old.

Claim 19 (original): The method of claim 5 wherein the human is an adult.

Claim 20 (original): The method of claim 12 wherein the human is a 2 to 3 year old.

Claim 27 (original): The method of claim 12 wherein the human is a 4 to 5 year old.

Claim 22 (original): The method of claim 12 wherein the human is a 5 to 14 year old.

Claim 23 (original): The method of claim 12 wherein the human is an adult.

Claim 24 (previously presented): The method of claim 1 wherein said Vi polysaccharide is covalently bound to the rEPA by means of an adipic acid dihydrazide linker.

Claim 25 (previously presented): The method of claim 12 wherein the S. typhi Vi polysaccharide is covalently bound to the *Pseudomonas aeruginosa* recombinant exoprotein A by means of an adipic acid dihydrazide linker.

WDN:SLR 11/25/03 234846 PATENT

Claim 26 (previously presented): The vaccine composition of claim 14 wherein the S. typhi Vi polysaccharide is covalently bound to the *Pseudomonas aeruginosa* recombinant exoprotein A by means of an adipic acid dihydrazide linker.

Claim 27 (new): The vaccine composition of claim 14, wherein the vaccine composition is a human vaccine composition.

Claim 28 (new): The vaccine composition of claim 26, wherein the vaccine composition is a human vaccine composition.

Page 5 of 9